

Resource Summary Report

Generated by [NIF](#) on Sep 1, 2026

BioLegend

RRID:SCR_001134

Type: Tool

Proper Citation

BioLegend (RRID:SCR_001134)

Resource Information

URL: <http://www.biolegend.com/>

Proper Citation: BioLegend (RRID:SCR_001134)

Description: Commercial antibody supplier and developer for biomedical research. These products are compatible with use in flow cytometry and mass cytometry, immunoprecipitation and chip, western blotting, immunofluorescence microscopy, and quantitative multiplexing.

Resource Type: commercial organization

Keywords: commercial, antibody, reagent, biomedical, research, san diego

Resource Name: BioLegend

Resource ID: SCR_001134

Alternate IDs: nlx_152302

Record Creation Time: 20220129T080205+0000

Record Last Update: 20260829T182036+0000

Ratings and Alerts

No rating or validation information has been found for BioLegend.

No alerts have been found for BioLegend.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 6621 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Mihajlovic K, et al. (2026) Dual CD73/A2AR blockade modulates the neurotoxic astrocyte phenotype without disrupting core inflammatory signaling. *Frontiers in pharmacology*, 17, 1778355.

Li N, et al. (2026) Pre-diagnostic metabolites in peripheral blood of Langerhans cell histiocytosis children with posterior pituitary involvement. *Metabolomics : Official journal of the Metabolomic Society*, 22(4).

Wang S, et al. (2025) IL-33 secreted from astrocytes alleviates cognitive impairment associated with neuropathic pain via oxidative stress in mice. *Journal of neurophysiology*, 133(6), 1919.

Chen Y, et al. (2025) A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia. *Cancer research*, 85(14), 2753.

Yu W, et al. (2025) Enhancing plasmacytoid dendritic cell functionality with all-trans retinoic acid for improved multiple myeloma therapy. *Molecular therapy. Oncology*, 33(2), 200992.

Brummel K, et al. (2025) Spatiotemporal Immune Landscape and Long-term Immune Memory in POLE-Mutant Endometrial Cancer at the Single-Cell Level. *Cancer immunology research*, 13(12), 1911.

Klemm N, et al. (2025) The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect. *Cancer research*, 85(11), 1978.

Lee SM, et al. (2025) Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 848.

Valvo VM, et al. (2025) Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. *Molecular cancer therapeutics*, 24(6), 843.

Choe M, et al. (2025) Preclinical Evaluation of Folate Receptor- γ Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma. *Cancer research communications*, 5(9), 1701.

Kollikowski AM, et al. (2024) MMP-9 release into collateral blood vessels before endovascular thrombectomy to assess the risk of major intracerebral haemorrhages and poor outcome for acute ischaemic stroke: a proof-of-concept study. *EBioMedicine*, 103, 105095.

Ferhat M, et al. (2023) The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis. *European journal of pharmacology*, 956, 175997.

Secker C, et al. (2023) The polyphenol EGCG directly targets intracellular amyloid- β aggregates and promotes their lysosomal degradation. *Journal of neurochemistry*.

Nelson MH, et al. (2023) The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies. *Molecular cancer therapeutics*, 22(1), 89.

Pouyababar D, et al. (2023) A rat liver cell atlas reveals intrahepatic myeloid heterogeneity. *iScience*, 26(11), 108213.

Rossmueller G, et al. (2023) Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic. *Molecular cancer therapeutics*, 22(5), 555.

Ogita T, et al. (2020) Oral Administration of Flavonifractor plautii Strongly Suppresses Th2 Immune Responses in Mice. *Frontiers in immunology*, 11, 379.

Yu N, et al. (2019) The Act1 D10N missense variant impairs CD40 signaling in human B-cells. *Genes and immunity*, 20(1), 23.

Heine W, et al. (2018) Loss of CNFY toxin-induced inflammation drives *Yersinia pseudotuberculosis* into persistency. *PLoS pathogens*, 14(2), e1006858.

Bretz CA, et al. (2018) Erythropoietin Signaling Increases Choroidal Macrophages and Cytokine Expression, and Exacerbates Choroidal Neovascularization. *Scientific reports*, 8(1), 2161.